Caron A. Jacobson, MD, Dana-Farber Cancer Institute

Articles by Caron A. Jacobson, MD, Dana-Farber Cancer Institute

R/R Large B-Cell Therapy in Managing Various Lymphomas

ByStephen J. Schuster, MD, Abramson Cancer Center,Caron A. Jacobson, MD, Dana-Farber Cancer Institute,Matthew J. Frigault, MD, Massachusetts General Hospital Cancer Center,David Miklos, MD, Stanford University,Loretta J. Nastoupil, MD, MD Anderson Cancer Center

July 2nd 2020

CAR T-Cell Therapy in Managing Various Lymphomas

ByStephen J. Schuster, MD, Abramson Cancer Center,Caron A. Jacobson, MD, Dana-Farber Cancer Institute,Matthew J. Frigault, MD, Massachusetts General Hospital Cancer Center,David Miklos, MD, Stanford University,Loretta J. Nastoupil, MD, MD Anderson Cancer Center

July 2nd 2020

Rationale for Further Development of CAR T-Cell therapy

ByStephen J. Schuster, MD, Abramson Cancer Center,Caron A. Jacobson, MD, Dana-Farber Cancer Institute,Matthew J. Frigault, MD, Massachusetts General Hospital Cancer Center,David Miklos, MD, Stanford University,Loretta J. Nastoupil, MD, MD Anderson Cancer Center

July 2nd 2020

Trending on OncLive

ASCO Issues First Guideline on ctDNA Testing in Solid Tumors and Lymphoma

Intismeran Autogene Plus Pembrolizumab Meets RFS and DMFS End Points in Resected Stage IIB-IV Melanoma

Darlifarnib Plus Cabozantinib Displays Early Signals of Safety and Efficacy in RCC

Five Under 5: Top Oncology Videos for the Week of 8/16

The OncFive: Top Oncology Articles for the Week of 8/16